William Stone; Chairman of the Board, Chief Executive Officer; SS&C Technologies Holdings Inc Rahul Kanwar; President, Chief Operating Officer; SS&C Technologies Holdings Inc Brian Schell; Chief ...

CSG expects 2025 revenue to range from $1.21 billion to $1.25 billion, with non-GAAP operating margins between 18.1% and 18.5%. The company anticipates non-GAAP EPS between $4.55 and $4.80 for 2025, ...

Management projects 2025 revenue between $6.085 billion and $6.245 billion, with organic growth at 5% at the midpoint. Adjusted EPS for the full year is expected to range from $5.64 to $5.96.

I’ll now turn it over to Brian to run through the financials ... Your first question comes from the line of Jeff Schmidt with William Blair. Please go ahead. Jeffrey Schmitt: Hi.

The firm says that while the rejection is a “major setback,” there is a possib RBC Capital analyst Brian Abrahams downgraded Applied Therapeutics (APLT) to Sector Perform from Outperform with ...

Neurocrine stock took a hit late Thursday after the biotech company issued a light 2025 outlook for its drug, Ingrezza.

Vertex Pharmaceuticals could soon capture $10 billion in sales of non-opioid painkillers, an analyst said Friday as Vertex stock jumped.